Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBIO iBio	$0.73 +27.2%	$0.76	$0.56 ▼ $6.89	$12.04M	0.6	1.41 million shs	2.21 million shs
INTI Inhibitor Therapeutics	$0.05 +19.5%	$0.05	$0.03 ▼ $0.10	$8.46M	-0.42	4,376 shs	11,600 shs
TAOX Synaptogenix	$9.56 +14.6%	$0.00	$1.84 ▼ $11.98	$11.59M	1.87	290,698 shs	463,660 shs
TRAW Traws Pharma	$1.64 +0.6%	$1.57	$0.97 ▼ $19.44	$9.07M	1.14	72,963 shs	112,385 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBIO iBio	-2.25%	-7.99%	-29.65%	-21.29%	-63.73%
INTI Inhibitor Therapeutics	+19.51%	-5.59%	-2.00%	-18.33%	-20.67%
TAOX Synaptogenix	+12.86%	+41.60%	+833,999,900.00%	+833,999,900.00%	+833,999,900.00%
TRAW Traws Pharma	+0.62%	+6.54%	+7.24%	+31.45%	+162,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IBIO iBio	1.111 of 5 stars	3.5	0.0	0.0	0.0	0.0	0.0	0.6
INTI Inhibitor Therapeutics	0.1376 of 5 stars	0.0	3.0	0.0	0.0	1.4	0.0	0.0
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	0.7391 of 5 stars	0.0	5.0	0.0	0.0	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBIO iBio	3.00	Buy	$5.00	585.87% Upside
INTI Inhibitor Therapeutics	0.00	N/A	N/A	N/A
TAOX Synaptogenix	0.00	N/A	N/A	N/A
TRAW Traws Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IBIO, TAOX, TRAW, and INTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBIO iBio	$375K	32.11	N/A	N/A	$1.41 per share	0.52
INTI Inhibitor Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.33 per share	N/A
TRAW Traws Pharma	$230K	39.65	N/A	N/A	($8.66) per share	-0.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
INTI Inhibitor Therapeutics	-$3.34M	-$0.01	N/A	∞	N/A	N/A	-120.86%	-55.21%	N/A
TAOX Synaptogenix	-$12.77M	-$10.08	N/A	∞	N/A	N/A	-115.28%	-58.31%	N/A
TRAW Traws Pharma	-$166.52M	-$32.81	N/A	N/A	N/A	-15,245.81%	N/A	-193.21%	8/14/2025 (Estimated)

Latest IBIO, TAOX, TRAW, and INTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	TRAW Traws Pharma	-$8.04	$2.09	+$10.13	$2.09	$0.06 million	$0.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBIO iBio	N/A	N/A	N/A	N/A	N/A
INTI Inhibitor Therapeutics	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBIO iBio	0.05	1.76	1.76
INTI Inhibitor Therapeutics	N/A	46.68	46.68
TAOX Synaptogenix	N/A	72.59	72.59
TRAW Traws Pharma	N/A	1.81	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBIO iBio	7.90%
INTI Inhibitor Therapeutics	N/A
TAOX Synaptogenix	10.34%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
IBIO iBio	0.58%
INTI Inhibitor Therapeutics	4.60%
TAOX Synaptogenix	2.73%
TRAW Traws Pharma	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBIO iBio	100	16.52 million	9.82 million	N/A
INTI Inhibitor Therapeutics	1	172.57 million	164.64 million	Not Optionable
TAOX Synaptogenix	4	1.39 million	1.35 million	N/A
TRAW Traws Pharma	17	5.56 million	4.81 million	Optionable

IBIO, TAOX, TRAW, and INTI Headlines

Recent News About These Companies

Traws Pharma to Announce Q2 Results and Business Update on August 14

August 10 at 3:07 AM | msn.com

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

August 8, 2025 | globenewswire.com

TRAW - Traws Pharma Inc Sustainability - Morningstar

July 16, 2025 | morningstar.comM

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma

July 8, 2025 | msn.com

Traws Pharma announces chief financial officer transition

July 5, 2025 | uk.investing.com

Traws Pharma, Inc. (TRAW) Income Statement - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Traws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

June 30, 2025 | finanznachrichten.de

Traws Pharma Submits Phase 2 Protocols for Tivoxavir Marboxil and Ratutrelvir to HREC and FDA

June 30, 2025 | quiverquant.comQ

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

June 30, 2025 | globenewswire.com

Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer

June 5, 2025 | msn.com

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

June 3, 2025 | globenewswire.com

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025 | globenewswire.com

Traws Pharma Unveils New Strategic Antiviral Focus

May 19, 2025 | tipranks.com

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments

May 18, 2025 | msn.com

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025 | globenewswire.com

Traws Pharma Appoints New Chairman Amid Leadership Changes

April 18, 2025 | tipranks.com

The Escalator: HHS, Spectrum Science, Alvotech and more

April 3, 2025 | mmm-online.comM

Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs

April 2, 2025 | msn.com

Traws Pharma reports FY24 EPS ($35.21)

April 1, 2025 | markets.businessinsider.com

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

April 1, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, TAOX, TRAW, and INTI Company Descriptions

iBio NYSE:IBIO

$0.73 +0.16 (+27.20%)

Closing price 04:00 PM Eastern

Extended Trading

$0.73 +0.00 (+0.14%)

As of 07:57 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Inhibitor Therapeutics OTCMKTS:INTI

$0.05 +0.01 (+19.51%)

As of 08/12/2025 02:40 PM Eastern

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

Synaptogenix NASDAQ:TAOX

$9.56 +1.22 (+14.63%)

As of 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Traws Pharma NASDAQ:TRAW

$1.64 +0.01 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 +0.06 (+3.35%)

As of 07:49 PM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time